Printer Friendly

Senti Biosciences Names Fischer as New Independent Board Member.

M2 PHARMA-June 14, 2019-Senti Biosciences Names Fischer as New Independent Board Member

(C)2019 M2 COMMUNICATIONS

- Dr. Laurent Fischer has joined US-based gene circuit company Senti Biosciences as an independent member of its board of directors, the company said.

Fischer is currently senior vice president and head of the liver therapeutic area at Allergan, and is also a senior advisor on the Frazier Healthcare Partners' Life Sciences team.

Fischer has more than 20 years of drug development and commercialisation experience in the biopharmaceutical industry. He was previously CEO of Tobira Therapeutics, which was acquired by Allergan for up to USD 1.7bn in 2016.

Prior to Tobira, Fischer was chairman and CEO of Jennerex, Inc., a company with a first-in-class oncolytic immunotherapy acquired for USD 150m by Sillajen. Prior to Jennerex, he was co-founder, president and CEO of Ocera Therapeutics.

Fischer has also held senior positions at DuPont-Merck, DuPont Pharmaceuticals, and Hoffmann-La Roche in liver disease, virology and oncology. He launched Sustiva, the first once-daily anti-HIV and the 10th top-prescribed specialty drug, in 2015, and was involved in the launch of the first protease inhibitor in the United States.

Fischer received his undergraduate degree from the University of Geneva and his medical degree from the Geneva Medical School, Switzerland.

Senti Biosciences is a next-generation therapeutics company that is developing gene circuits and programming cells for tremendous therapeutic value.

The company is based in South San Francisco and was founded in 2016 by Drs. Tim Lu, Philip Lee, Jim Collins and Wilson Wong. Senti is proud to count NEA, 8VC, Amgen Ventures, Pear Ventures, Lux Capital, Menlo Ventures, Pear Ventures, Allen and company, Nest.Bio, Omega Funds, Goodman Capital, and LifeForce Capital among their investors.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2019 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Jun 14, 2019
Words:295
Previous Article:Agilent Companion Diagnostic Gains Expanded FDA Approval in Head and Neck Squamous Cell Carcinoma.
Next Article:Seattle Genetics Makes Multiple Adcetris Presentations at the Congress of the European Hematology Association and the International Conference on...

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters